Eledon Pharmaceuticals, Inc. Common Stock
Here’s whether Eledon Pharmaceuticals, Inc. Common Stock (ELDN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.79% over 10 days); strong 1-year return of +32.7%; 3-month momentum positive (+87.7%). Concerns: RSI 83 — overbought, elevated pullback risk. Currently 13.5% off its 52-week high. Score: +5/7.
ELDN is in a confirmed uptrend, trading above both its 50-day ($2.72) and 200-day ($2.60) moving averages. With an RSI of 83.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +32.7% compares to +35.1% for SPY (trailed the market by 2.4%).